This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Carter, G. T. Articles by Weiss, M. D. Search for Related Content PubMed PubMed Citation Articles by Carter, G. T. Articles by Weiss, M. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Charcot-Marie-Tooth Disease Genetics Home Reference Genetics Home Reference - Charcot-Marie-Tooth disease Social Bookmarking                         What's this?

Modafinil Reduces Fatigue in Charcot-Marie-Tooth Disease Type 1A: A Case Series

Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington, gtcarter{at}u.washington.edu

Jay J. Han, MD

Departments of Physical Medicine and Rehabilitation, University of California, Davis School of Medicine, Davis, California

Angeli Mayadev, MD

Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington

Michael D. Weiss, MD

Department of Neurology, University of Washington School of Medicine, Seattle, Washington

Charcot-Marie-Tooth disease, the most common hereditary motor and sensory neuropathy, is a slowly progressive disorder characterized by diffuse muscle weakness and prominent distal atrophy that predominantly involves the intrinsic muscles of the feet and the peroneal muscles. It results in marked reduction in functional aerobic capacity during exercise and fatigue is commonly reported. To date, no pharmacologic treatment has been shown to be effective for treating fatigue in Charcot-Marie-Tooth. Modafinil is used to treat the symptoms of fatigue and excessive daytime sleepiness in narcolepsy. However, fatigue and subsequent excessive daytime sleepiness secondary to fatigue are common symptoms in many neurologic disorders. Prior reports on patients with myotonic muscular dystrophy, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis, have shown beneficial effects of modafinil in treating fatigue. We report 4 patients with genetically confirmed Charcot-Marie-Tooth disease who had significant fatigue that was almost completely relieved by modafinil.

Key Words: Charcot-Marie-Tooth disease • hereditary motor and sensory neuropathy • fatigue

American Journal of Hospice and Palliative Medicine®, Vol. 23, No. 5, 412-416 (2006)
DOI: 10.1177/1049909106292169


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?